## Neurology Order Form





Fax completed form to:

All Allierta Company				
PATIENT INFORMATION				
Patient Name:	Date of Birth:		Referral Date:	
Address:		City/State/Zip	):	
Home Phone:	Cell Phone:		Work Phone:	
Secondary Contact:	Height: Weight:	ght:	Male Female	
Patient Diagnosis & ICD-1	10:			
Allergies:				
PROVIDER INFORMATION				
Physician Name:	Lic.#:	DEA #:		
Practice Name:		NPI#:		
Address:	City/State/Zip:			
Office Contact:	Phone: Fax:		Fax:	
Supervisory Physician (if applicable):				
PLEASE ATTACH				
Patient demographics & front/back copy of all insurance cards (prescription & medical)  Vaccine status (any vaccination) and documentation of any recent vaccinations				
Recent office visit notes, history & physical, lab & pertinent procedure results  HBV lab results within last 12 months ( <i>Uplizna only</i> )				
Current medication list & list of prior medications tried and failed (with dates)  Date of diagnosis, current FVC%, ALSFRS-R score, and JourneyMate form (Radicava only)				
Line access documentation/verification if applicable  Anti-acetylcholine receptor (AChR) antibody positive results (Vyvqart)				
Quantitative serum Immunoglobulin lab results ( <i>Uplizna only</i> )  Letter of medical necessity if drug dosing or indication is outside of FDA guidelines				
TB lab results within last 12 months ( <i>Uplizna only</i> )				
NURSING & LAB ORDERS				
Nurse Orders: Nurse to provide assessment, teaching, lab draws, medication administration and vascular access device insertion and/or management per physician orders.				
Flush Orders: NaCl 0.9% - 5-10mL flush pre and post infusion and as needed Heparin - 10units/mLOR 100units/mL - 3-5mL flush after post-infusion NS flush if indicated to maintain line				
Lab Orders: Lab Date & Frequency:				
PRESCRIPTION ORDERS				
Anaphylaxis Kit: Epinephrine 0.3mg IM as needed Solu-cortef 250mg-500mg IV as needed Solu-Medrol 60mg - 125mg IV as needed				
(Check all that apply)	Diphenhydramine mg IV as needed			
Pre-Medications:	Acetaminophenmq POminutes prior to infusion Solu-Medrolmq IVminutes prior to infusion			
(Check all that apply) Diphenhydraminemg PO OR IVminutes prior to infusion Other				
Supply Orders: All supplies for vascular access line care, drug administration kit(s), pump, and IV pole will be provided as necessary				
PRODUCT		ON INFORMATION		REFILLS
PRODUCI	PRESCRIPTO	UNINFURMATION		KEFILLS
Is this a first dose? Yes No If No, when was last dose given? When is patient due for next dose?				
RADICAVA	Induction: 60mg IV infusion via gravityOR pump over 1 h	our daily for 14 days followed by 14 da	ny drug-free period	NONE
	Maintenance: 60mg IV infusion via gravity OR pump over 1 hour daily for 10 days out of 14 day period followed by 14 day drug-free periods			
UPLIZNA	Induction: 300mg IV infusion via gravityOR pump over approximately 90 minutes at 0 and 2 weeks and CBC lab testing everymonths			NONE
UPLIZNA	Maintenance: (starting 6 months from first infusion) 300mg IV infusion vi	ia gravity <b>0R</b> pump over	r approximately 90 minutes every 6 months	
VAVEDTI	100mg IV infusion via gravity OR pump over approximately 30 minutes every 12 weeks			
VYEPTI	300mg IV infusion via gravity OR pump over approximately 3	30 minutes every 12 weeks		
	10mg/kg IV infusion via gravity OR pump over at least 1 ho	<u> </u>		
VYVGART	*Up to max of 1200mg for patient weight of 120kg+ (Total volume is 125ml in	•		
	Administer additional treatment cycles every 50 days OR Prescriber to evaluate treatment cycle frequency after completion of initial treatment cycle			
	According to the Package Insert: Administer subsequent treatment cycles based on clinical evaluation; the safety of initiating subsequent cycles sooner than 50 days			
	from the start of the previous treatment cycle has not been established.	, ···,		
VYVGART HYTRULO	1,008mg/11,200 units subcutaneous injection over approximately 30 to 90 se	econds in cycles of once weekly inject	ions for 4 weeks	
	Administer additional treatment cycles every 50 days OR Prescriber to evaluate treatment cycle frequency after completion of initial treatment cycle			
	According to the Package Insert: Administer subsequent treatment cycles based on clinical evaluation; the safety of initiating subsequent cycles sooner than 50 days			
	from the start of the previous treatment cycle has not been established.			
IG	Refer to Immunoglobulin Form			
SOLIRIS/ULTOMIRIS	Refer to Soliris or Ultomiris Order Form			
OTHER				NONE
By signing this form and utilizing our services, you are authorizing Mosaic to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies.				
, , , , , , , , , , , , , , , , , , ,				

ACCREDITED Specially Pharmocy

Date



Date

mosaiciv.com